血管内皮生长因子及其受体与上皮性卵巢癌发展

Relations between the expression of VEGF and its receptor KDR and the progression of epithelial ovarian cancer

目的 探讨血管内皮生长因子 (VEGF)及其受体 (KDR)与上皮性卵巢癌发展的关系。方法 用免疫组化方法检测 4 5例人上皮性卵巢癌中VEGF及KDR的表达 ,分析VEGF及KDR表达与卵巢癌FIGO分期、淋巴结转移及预后的关系。结果 4 5例上皮性卵巢癌中 ,VEGF、KDR表达阳性率分别为 73.3% (33/ 4 5 )、5 7.8% (2 6 / 4 5 )。Ⅲ～Ⅳ期卵巢癌VEGF表达阳性率 (94 .4 % ,17/ 18)高于Ⅰ～Ⅱ期卵巢癌 (5 9.3% ,16 / 2 7)。淋巴结转移阳性组中VEGF表达阳性率 (10 0 % ,12 / 12 )高于淋巴结转移阴性组 (16 / 2 6 ,6 1.5 % ) ,(P <0 .0 5 )。VEGF表达阴性者生存率高于VEGF表达阳性者 (P =0 .0 4 7)。不同组织学类型上皮性卵巢癌中VEGF表达无明显差异。KDR表达与卵巢癌分期、淋巴转移及预后无关。结论 VEGF与上皮性卵巢癌发展有关。

ObjectiveTo investigate the relationship between the expression of VEGF and its receptor KDR and the progression of epithelial ovarian cancer. MethodsThe expression of VEGF and its receptor KDR was examined immunohistochemically in 45 cases of epithelial ovarian cancer. The relationships between the expression of VEGF and KDR, clinicopathological factors, lymphatic metastasis and patient survival were analyzed. ResultsPositive immunostainings for VEGF and KDR were 73.3%(33 /45) and 57.8%(26 /45) respectively. VEGF+immunostaining was observed more frequently in the advanced stage of the disease and the lymphatic metastasis group. Patients with positive VEGF immunostaining showed poorer prognosis than those stained negatively. There was no relationship between the expression of KDR and lymphatic metastasis nor patient survival. ConclusionThere is a close relationship between VEGF expression and tumor progression in epithelia ovarian cancer patients.